Androgen Deprivation Therapy and the Re-em... [Oncol Hematol Rev. 2014] - PubMed - NCBI - 0 views
-
Nathan Goodyear on 08 Jul 14Sometimes I think medicine has lost its mind. Or at least, it is not thinking things through. To give IV estrogen to decrease Testosteorne in men with prostate cancer is devoid of the pathophysiology of prostate cancer and cardiovascular disease in men. Elevated Estradiol in men increases CRP, IL-1beta, and TNF-alpha to name a few cytokines. The proported purpose of the IV estrogen is to prevent the cardiovascular complications associated with ADT. Yet, elevated aromatase activity and low T in men are both shown to be associated with increased CVD in men.